study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

Cetrotide

no Cetrotide

Total

Sex: Female, Male

Race (NIH/OMB)

Region of Enrollment

Serum E2 levels (Serum E2 level in picograms/ml) were evaluated daily.

Daily Serum E2 Levels

MOD (maximal ovarian diameter in mm) were evaluated daily.

Daily Maximal Ovarian Diameter

-All patients were clinically evaluated for the presence of abdominal pain and if present was graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10 means severe intolerable pain .

study group (24 patients = intervention) received intervention for 3-days Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

Daily Numerical Pain Visual Analogue Scale Score

Blood samples were obtained under complete aseptic condition for determination of hematocrits value (Ht%)

Daily Hematocrits Value

-US detected severity grades of ascites determined at Day -0, Day -3 and Day -8.

Ultrasound Detected Severity Grades of Ascites From Days 0-8

Daily Total Leucocytic Count

-severity grades of gastrointestinal manifestations determined at Day -0,Day -3 and Day -6.

Resolution of Gastrointestinal Manifestations Determined Prior to Start of Therapy

study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD(maximal ovarian diameter) were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.

Overall Study

dr khalid M Salama

Infertility

study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.

Cetrorelix

Benha university hospitalا

Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

khalid mohammed salama

director clinical research

Benha University

Fontan Patients with Protein Losing Enteropathy and Plastic Bronchitis

Protein Losing Enteropathy and Plastic Bronchitis

2 ventricle heart with Atrial Septal Defect

Fontan Physiology Patients With PB or PLE

Fontan Physiology Patients Without PB or PLE

Children's Hospital of Wisconsin

Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology

An Investigation Into The Potential Roles Of Vasoactive Intestinal Peptide And Substance P In The Pathophysiology Of Plastic Bronchitis And Protein Losing Enteropathy In Children With Palliated Single Ventricle Physiology

It is anticipated that results will demonstrate significant differences in venous, arterial and /or transpulmonary levels of VIP, Substance P or both among the various subject groups reflecting etiologic factors in the development of PLE and PB in patients with Fontan physiology.

William Clarke

Associate Professor, Anesthesiology/Clinical/Pediatrics

Medical College of Wisconsin

Children's Hospital and Health System Foundation, Wisconsin

Gastrointestinal Stromal Tumors

imatinib mesylate

J Clin Oncol 30, 2012 (suppl; abstr e20514) (From 2012 ASCO Annual Meeting )

See results for CSTI571BIC08 at Novartis Clinical Trials Database

Novartis Investigative Site

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)

A Multi-center, Single Arm, Phase II Study of Adjuvant Imatinib (Glivec®) in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor ( GIST)

pericardial effusion/diarrhea

Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)

科學支持的最完整的草藥數據庫